Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization
NCT03042871
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
54
Enrollment
OTHER
Sponsor class
Conditions
Choroidal Neovascularization
Interventions
DRUG:
0.5mg intravitreal ranibizumab
Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University